companies / abbratech-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-05-05 json
| total_raised | 2,243,9422.2M | ○ |
|---|---|---|
| founded | 2020 | |
| hq | Guilford, Connecticut, USA | |
| industry | unknown | |
| stage | null |
AbbraTech is a biotech firm specializing in recombinant antibody discovery through its Epivolve platform. It serves pharmaceutical and academic partners developing therapeutics for cancer, immune disorders, and viral infections. Its platform reaches disease targets that conventional methods cannot, overcoming immunogenicity and immune tolerance.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2023-09-01 | grant | 2,200,0002.2M | null | ○ |
Cloudflare, reCAPTCHA, Site Kit 1.179.0, jQuery Migrate 3.4.1, Elementor 4.0.9, Cloudflare Bot Management, WordPress, Python, PHP, MySQL, jquery 3.7.1
| fact | status | src |
|---|---|---|
| Grant, $2.2M | attributed | ○ |
| existence | sourced | WEB |
| description | self-reported | WEB |
| date | fact | change | src |
|---|---|---|---|
| 2026-10-17provenance_existence: self-reported → sourced, WEB 2026-10-17 | provenance_existence | self-reported → sourced | WEB 2026-10-17 |
Records begin 2026-09-24. all_changes